These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21674650)

  • 1. Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
    Lemasson B; Christen T; Tizon X; Farion R; Fondraz N; Provent P; Segebarth C; Barbier EL; Genne P; Duchamp O; Remy C
    NMR Biomed; 2011 Jun; 24(5):473-82. PubMed ID: 21674650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting and monitoring response to chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea in subcutaneously implanted 9L glioma using the apparent diffusion coefficient of water and 23Na MRI.
    Babsky AM; Hekmatyar SK; Zhang H; Solomon JL; Bansal N
    J Magn Reson Imaging; 2006 Jul; 24(1):132-9. PubMed ID: 16758478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MRI as an early biomarker of individual therapy effects during concomitant treatment of brain tumours.
    Lemasson B; Bouchet A; Maisin C; Christen T; Le Duc G; Rémy C; Barbier EL; Serduc R
    NMR Biomed; 2015 Sep; 28(9):1163-73. PubMed ID: 26224287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
    Flaherty KT; Rosen MA; Heitjan DF; Gallagher ML; Schwartz B; Schnall MD; O'Dwyer PJ
    Cancer Biol Ther; 2008 Apr; 7(4):496-501. PubMed ID: 18219225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
    Lemasson B; Serduc R; Maisin C; Bouchet A; Coquery N; Robert P; Le Duc G; Troprès I; Rémy C; Barbier EL
    Radiology; 2010 Nov; 257(2):342-52. PubMed ID: 20829544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
    Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
    J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study.
    Valable S; Lemasson B; Farion R; Beaumont M; Segebarth C; Remy C; Barbier EL
    NMR Biomed; 2008 Nov; 21(10):1043-56. PubMed ID: 18615861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
    Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA
    AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring early response to anti-angiogenic therapy: diffusion-weighted magnetic resonance imaging and volume measurements in colon carcinoma xenografts.
    Schneider MJ; Cyran CC; Nikolaou K; Hirner H; Reiser MF; Dietrich O
    PLoS One; 2014; 9(9):e106970. PubMed ID: 25222284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice.
    Ullrich RT; Jikeli JF; Diedenhofen M; Böhm-Sturm P; Unruh M; Vollmar S; Hoehn M
    PLoS One; 2011 May; 6(5):e19592. PubMed ID: 21573168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
    Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
    Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib exerts anti-glioma activity in vitro and in vivo.
    Siegelin MD; Raskett CM; Gilbert CA; Ross AH; Altieri DC
    Neurosci Lett; 2010 Jul; 478(3):165-70. PubMed ID: 20470863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the relationship between MR estimates of blood oxygen saturation and hypoxia: effect of an antiangiogenic treatment on a gliosarcoma model.
    Lemasson B; Christen T; Serduc R; Maisin C; Bouchet A; Le Duc G; Rémy C; Barbier EL
    Radiology; 2012 Dec; 265(3):743-52. PubMed ID: 22996750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
    Righi M; Giacomini A; Lavazza C; Sia D; Carlo-Stella C; Gianni AM
    Lab Invest; 2009 Sep; 89(9):1063-70. PubMed ID: 19652644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
    Cyran CC; Schwarz B; Paprottka PM; Sourbron S; von Einem JC; Dietrich O; Hinkel R; Clevert DA; Bruns CJ; Reiser MF; Nikolaou K; Wintersperger BJ
    Cancer Imaging; 2013 Dec; 13(4):557-66. PubMed ID: 24380871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent treatment with BCNU and Gamma Knife radiosurgery in the rat malignant glioma model.
    Cho KT; Kim DG; Paek SH; Chung HT; Jung HW; Park HW
    J Neurol Surg A Cent Eur Neurosurg; 2012 May; 73(3):132-41. PubMed ID: 22628080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment.
    Fan CH; Ting CY; Liu HL; Huang CY; Hsieh HY; Yen TC; Wei KC; Yeh CK
    Biomaterials; 2013 Mar; 34(8):2142-55. PubMed ID: 23246066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
    Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
    Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.